During the last session, Esperion Therapeutics Inc. (NASDAQ:ESPR)’s traded shares were 1.73 million, with the beta value of the company hitting 0.10. At the end of the trading day, the stock’s price was $1.58, reflecting an intraday loss of -3.07% or -$0.05. The 52-week high for the ESPR share is $8.87, that puts it down -461.39 from that peak though still a striking 29.11% gain since the share price plummeted to a 52-week low of $1.12. The company’s market capitalization is $155.60M, and the average intraday trading volume over the past 10 days was 2.03 million shares, and the average trade volume was 4.19 million shares over the past three months.
Esperion Therapeutics Inc. (ESPR) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 2.40. ESPR has a Sell rating from 1 analyst(s) out of 10 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 1 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.6.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Esperion Therapeutics Inc. (NASDAQ:ESPR) trade information
Esperion Therapeutics Inc. (ESPR) registered a -3.07% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.07% in intraday trading to $1.58 this Wednesday, 05/24/23, hitting a weekly high. The stock’s 5-day price performance is -10.23%, and it has moved by 31.67% in 30 days. Based on these gigs, the overall price performance for the year is -74.43%. The short interest in Esperion Therapeutics Inc. (NASDAQ:ESPR) is 15.66 million shares and it means that shorts have 6.1 day(s) to cover.
The consensus price target of analysts on Wall Street is $10.19, which implies an increase of 84.49% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1.00 and $22.00 respectively. As a result, ESPR is trading at a discount of -1292.41% off the target high and 36.71% off the low.
Esperion Therapeutics Inc. (ESPR) estimates and forecasts
Statistics show that Esperion Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Esperion Therapeutics Inc. (ESPR) shares have gone down -76.49% during the last six months, with a year-to-date growth rate more than the industry average at 38.35% against 13.20. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to grow 42.90% this quarter and then jump 42.00% in the quarter after that. In the rating firms’ projections, revenue will increase 61.20% compared to the previous financial year.
Revenue for the current quarter is expected to be $26 million as predicted by 9 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to $32.01 million by the end of Sep 2023. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $18.84 million and $19.91 million respectively. In this case, analysts expect current quarter sales to grow by 38.00% and then jump by 60.80% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 12.80%. While earnings are projected to return 62.20% in 2023, the next five years will return 16.90% per annum.
Esperion Therapeutics Inc. is due to release its next quarterly earnings on May 09. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Esperion Therapeutics Inc. (NASDAQ:ESPR)’s Major holders
Esperion Therapeutics Inc. insiders own 0.45% of total outstanding shares while institutional holders control 97.36%, with the float percentage being 97.80%. Wasatch Advisors LP is the largest shareholder of the company, while 225 institutions own stock in it. As of Mar 30, 2023, the company held over 13.35 million shares (or 14.10% of all shares), a total value of $21.23 million in shares.
The next largest institutional holding, with 4.82 million shares, is of Blackrock Inc.’s that is approximately 5.09% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $7.67 million.
Also, the Mutual Funds coming in first place with the largest holdings of Esperion Therapeutics Inc. (ESPR) shares are Vanguard Total Stock Market Index Fund and Wasatch Ultra Growth Fund. Data provided on Dec 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 2.22 million shares. This amounts to just over 2.89 percent of the company’s overall shares, with a $13.81 million market value. The same data shows that the other fund manager holds slightly less at 1.65 million, or about 2.16% of the stock, which is worth about $10.31 million.